Crossmark

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition

Crossref DOI link: https://doi.org/10.1186/s40425-019-0758-y

Published Online: 2019-10-25

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mao, Wendy

Ghasemzadeh, Ali

Freeman, Zachary T.

Obradovic, Aleksandar

Chaimowitz, Matthew G.

Nirschl, Thomas R.

McKiernan, Emily

Yegnasubramanian, Srinivasan

Drake, Charles G.
Funding

Funding for this research was provided by:

Prostate Cancer Foundation
License Information

Text and Data Mining valid from 2019-10-25
More Information

Article History

Received: 28 February 2019

Accepted: 26 September 2019

First Online: 25 October 2019

Ethics approval and consent to participate

: All animal experiments were performed in specific pathogen-free facilities accredited by the American Association for the Accreditation of Laboratory Animal Care (AAALAC) with protocols approved by the Animal Care and Use Committee of the Columbia University School of Medicine (New York, NY).

: Not applicable.

: The authors declare competing financial interests. CGD has consulted for Amplimmune, Bristol Myers Squibb (BMS), Merck, and Roche-Genentech, all of whom have either anti-PD-1 or anti-PD-L1 reagents in various stages of clinical development. In addition, CGD has previously received sponsored research funding from BMS. WM has no conflicts of interest to declare.